Common use of General Observations and Clarifications Clause in Contracts

General Observations and Clarifications. For the sake of good order it is hereby clarified that, unless otherwise agreed upon in writing by BioCancell: 6.1. No payment would be performed for any activities performed by the Principal Investigator and/or by the Medical Center, prior to the commencement of the Trial. 6.2. Without derogating from any right of BioCancell, in the event that no Completed CRF’s are provided to BioCancell, regarding a Subject, in relation to which BioCancell has performed payments to the Medical Center, BioCancell shall be entitled to perform one of the following three, according to its absolute discretion: 6.2.1. Write-off the amount paid by BioCancell in relation to Subject(s) for which no Completed CRFs have been provided (hereinafter: “the Return Amount”) from the amount remaining due to the Medical Center by BioCancell according to this Agreement (hereinafter: “the Remaining Amount”). 6.2.2. Order the Medical Center, in writing, to pay BioCancell the Return Amount within a period no longer than 45 (forty-five) days from the End of the Trial. The Medical Center hereby undertakes that it shall pay the Return Amount, as specified above, and renounces any contentions and/or claims whatsoever in relation thereto. 6.2.3. In the event that the Return Amount shall exceed the Remaining Amount, BioCancell shall be entitled to exercise its rights under the above sub-sections 6.3.1 and 6.3.2 in concert, to the extent that BioCancell shall fully collect the Return Amount from the Medical Center. 6.3. No advance payments would be performed by BioCancell to the Medical Center. Template – agreement with medical centers The protocol name and number: BC-07-01 Name of the investigational product: DTA-H19/PEI Name of the Principal Investigator: Department: Urology Name of the medical institution: The Sponsor’s name and address: BioCancell Therapeutics Ltd., Xxxx Science Center, 0 Xxxxxx Xx., Xxxxxxxxx 00000, Xxxxxx 1. Sponsor undertaking 1.1.1. Responsibility for the safety and good order of the investigational product; 1.1.2. Supply of information regarding the trial; 1.1.3. Notice to the Ministry of Health regarding the performance of a multi-centre trial in Israel; 1.1.4. Monitoring the trial process; 1.1.5. Safety reports; 1.1.6. Accountability in respect of the investigational product;

General Observations and Clarifications. For the sake of good order it is hereby clarified that, unless otherwise agreed upon in writing by BioCancell: 6.1. No payment would be performed for any activities performed by the Principal Investigator and/or by the Medical CenterClinical Trial Site, prior to the commencement of the Trial. 6.2. Without derogating from any right of BioCancell, in the event that no Completed CRF’s are provided to BioCancell, regarding a Subject, in relation to which BioCancell has performed payments to the Medical CenterClinical Trial Site, BioCancell shall be entitled to perform one of the following three, according to its absolute discretion: 6.2.1. Write-off the amount paid by BioCancell in relation to Subject(s) for which no Completed CRFs have been provided (hereinafter: “the Return Amount”) from the amount remaining due to the Medical Center Clinical Trial Site by BioCancell according to this Agreement (hereinafter: “the Remaining Amount”). 6.2.2. Order the Medical CenterClinical Trial Site, in writing, to pay BioCancell the Return Amount within a period no longer than 45 (forty-five) days from the End of the Trial. The Medical Center Clinical Trial Site hereby undertakes that it shall pay the Return Amount, as specified above, and renounces any contentions and/or claims whatsoever in relation thereto. 6.2.3. In the event that the Return Amount shall exceed the Remaining Amount, BioCancell shall be entitled to exercise its rights under the above sub-sections 6.3.1 and 6.3.2 in concert, to the extent that BioCancell shall fully collect the Return Amount from the Medical CenterClinical Trial Site. 6.3. No advance payments would be performed by BioCancell to the Medical Center. Template – agreement with medical centers The protocol name and number: BC-07-01 Name of the investigational product: DTA-H19/PEI Name of the Principal Investigator: Department: Urology Name of the medical institution: The Sponsor’s name and address: BioCancell Therapeutics Ltd., Xxxx Science Center, 0 Xxxxxx XxClinical Trial Site., Xxxxxxxxx 00000, Xxxxxx 1. Sponsor undertaking 1.1.1. Responsibility for the safety and good order of the investigational product; 1.1.2. Supply of information regarding the trial; 1.1.3. Notice to the Ministry of Health regarding the performance of a multi-centre trial in Israel; 1.1.4. Monitoring the trial process; 1.1.5. Safety reports; 1.1.6. Accountability in respect of the investigational product;

General Observations and Clarifications. For the sake of good order it is hereby clarified that, unless otherwise agreed upon in writing by BioCancell: 6.1. No payment would be performed for any activities performed by the Principal Investigator and/or by the Medical Center, prior to the commencement of the Trial. 6.2. Without derogating from any right of BioCancell, in the event that no Completed CRF’s are provided to BioCancell, regarding a Subject, in relation to which BioCancell has performed payments to the Medical Center, BioCancell shall be entitled to perform one of the following three, according to its absolute discretion: 6.2.1. Write-off the amount paid by BioCancell in relation to Subject(s) for which no Completed CRFs CRF’s have been provided (hereinafter: “the Return Amount”) from the amount remaining due to the Medical Center by BioCancell according to this Agreement (hereinafter: “the Remaining Amount”). 6.2.2. Order the Medical Center, in writing, to pay BioCancell the Return Amount within a period no longer than 45 (forty-five) days from the End of the Trial. The Medical Center hereby undertakes that it shall pay the Return Amount, Amount as specified above, and renounces any contentions and/or claims whatsoever in relation thereto. 6.2.3. In the event that the Return Amount shall exceed the Remaining Amount, BioCancell shall be entitled to exercise its rights under the above sub-sections 6.3.1 and 6.3.2 in concert, to the extent that BioCancell shall fully collect the Return Amount from the Medical Center. 6.3. No advance payments would be performed by BioCancell to the Medical Center. Template Bnai Zion – final agreement with medical centers The protocol name and number: BC-07-01 Name of the investigational product: DTA-H19/PEI Name of the Principal Investigator: Department: Urology Name of the medical institutionInstitution: The Sponsor’s name and address: BioCancell Therapeutics Ltd., Xxxx Science Center, 0 Xxxxxx Xx., Xxxxxxxxx 00000, Xxxxxx 1. Sponsor undertaking 1.1.1. Responsibility for the safety and good order of the investigational product; 1.1.2. Supply of information regarding the trial; 1.1.3. Notice to the Ministry of Health regarding the performance of a multi-centre multicentre trial in Israel; 1.1.4. Monitoring the trial process; 1.1.5. Safety reports; 1.1.6. Accountability in respect of the investigational product;

General Observations and Clarifications. For the sake of good order it is hereby clarified that, unless otherwise agreed upon in writing by BioCancell: 6.1. No payment would be performed for any activities performed by the Principal Investigator and/or by the Medical CenterFund, prior to the commencement of the Trial. 6.2. Without derogating from any right of BioCancell, in the event that no Completed CRF’s are provided to BioCancell, regarding a Subject, in relation to which BioCancell has performed payments to the Medical CenterFund, BioCancell shall be entitled to perform one of the following three, according to its absolute discretion: 6.2.1. Write-off the amount paid by BioCancell in relation to Subject(s) for which no Completed CRFs CRF’s have been provided (hereinafter: “the Return Amount”) from the amount remaining due to the Medical Center Fund by BioCancell according to this Agreement (hereinafter: “the Remaining Amount”). 6.2.2. Order the Medical CenterFund, in writing, to pay BioCancell the Return Amount within a period no longer than 45 (forty-five) days from the End of the Trial. The Medical Center Fund hereby undertakes that it shall pay the Return Amount, as specified above, and renounces any contentions and/or claims whatsoever in relation thereto. 6.2.3. In the event that the Return Amount shall exceed the Remaining Amount, BioCancell shall be entitled to exercise its rights under the above sub-sections 6.3.1 and 6.3.2 in concert, to the extent that BioCancell shall fully collect the Return Amount from the Medical CenterFund. 6.3. No advance payments would be performed by BioCancell to the Medical CenterFund. Template – agreement with medical centers The protocol name and number: BC-07-01 Name of the investigational product: DTA-H19/PEI Name of the Principal Investigator: Department: Urology Name of the medical institution: The Sponsor’s name and address: BioCancell Therapeutics Ltd., Xxxx Science Center, 0 Xxxxxx Xx., Xxxxxxxxx 00000, Xxxxxx 1. Sponsor undertaking 1.1.1. Responsibility for the safety and good order of the investigational product; 1.1.2. Supply of information regarding the trial; 1.1.3. Notice to the Ministry of Health regarding the performance of a multi-centre multicenter trial in Israel; 1.1.4. Monitoring the trial process; 1.1.5. Safety reports; 1.1.6. Accountability in respect of the investigational product;

General Observations and Clarifications. For the sake of good order it is hereby clarified that, unless otherwise agreed upon in writing by BioCancell: 6.1. No payment would be performed for any activities performed by the Principal Investigator and/or by the Medical Center, prior to the commencement of the Trial. 6.2. Without derogating from any right of BioCancell, in the event that no Completed CRF’s 's are provided to BioCancell, regarding a Subject, in relation to which BioCancell has performed payments to the Medical Center, BioCancell shall be entitled to perform one of the following three, according to its absolute discretion: 6.2.1. Write-off the amount paid by BioCancell in relation to Subject(s) for which no Completed CRFs have been provided (hereinafter: “the Return Amount”) from the amount remaining due to the Medical Center by BioCancell according to this Agreement (hereinafter: “the Remaining Amount”). 6.2.2. Order the Medical Center, in writing, to pay BioCancell the Return Amount within a period no longer than 45 (forty-five) days from the End of the Trial. , The Medical Center hereby undertakes that it shall pay the Return Amount, as specified above, and renounces any contentions and/or claims whatsoever in relation thereto. 6.2.3. In the event that the Return Amount shall exceed the Remaining remaining Amount, BioCancell shall be entitled to exercise its rights under the above sub-sections 6.3.1 and arid 6.3.2 in concert, to the extent that BioCancell shall fully collect the Return Amount from the Medical Center. 6.3. No advance payments would be performed by BioCancell to the Medical Center. Template – Meir-final agreement 0 Xxxxxx Xx, Xxxxxxxxx Xxxxxx 00000 Phone: +000-0-000-0000 Fax: +000-0-000-0000 xxx.xxxxxxxxxx.xxx xxxx@xxxxxxxxxx.xxx Title of the trial: “Phase 2b, Multicenter Trial of Intravesical DTA-H19/PEI in Patients with medical centers Intermediate-Risk Superficial Bladder Cancer” The protocol name and number: BC-07-01 Name of the investigational product: DTA-H19/PEI Name of the Principal Investigator: Department: Urology Name of the medical institution: The Sponsor’s name and address: BioCancell Therapeutics Ltd., Xxxx Science Center, 0 Xxxxxx Xx., Xxxxxxxxx 00000, Xxxxxx 1. Sponsor undertaking 1.1.1. Responsibility for the safety and good order of the investigational product; 1.1.2. Supply of information regarding the trial; 1.1.3. Notice to the Ministry of Health regarding the performance of a multi-centre trial in Israel; 1.1.4. Monitoring the trial process; 1.1.5. Safety reports; 1.1.6. Accountability in respect of the investigational product;